Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 1
1984 2
1986 1
1987 1
1988 1
1992 1
1995 1
1996 1
1997 2
1999 2
2000 1
2002 1
2003 1
2006 2
2007 3
2011 2
2013 1
2014 1
2015 1
2016 2
2017 2
2018 1
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
[Neuroendocrine Neoplasia within the German NET Registry].
Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers, et al. Z Gastroenterol. 2018 Oct;56(10):1237-1246. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. Z Gastroenterol. 2018. PMID: 30304748 German.
Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice.
Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D, Quietzsch D, Grabowski P, Cremer B, Maasberg S, Pape UF, Mueller HH, Gress TM, Rinke A, The Members Of The German Net Registry. Luecke S, et al. Among authors: quietzsch d. Cancers (Basel). 2022 May 31;14(11):2718. doi: 10.3390/cancers14112718. Cancers (Basel). 2022. PMID: 35681701 Free PMC article.
[Immunomodulation with apheresis technics].
Liebert A, Quietzsch D, Zimmermann S. Liebert A, et al. Among authors: quietzsch d. Allerg Immunol (Leipz). 1986;32(1):5-18. Allerg Immunol (Leipz). 1986. PMID: 2940851 Review. German.
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen CB, Siveke JT, Wenzel P, Schlitter AM, Esposito I, Quietzsch D, Clemens MR, Kettner E, Laubender RP, Jung A, Kirchner T, Boeck S, Heinemann V. Haas M, et al. Among authors: quietzsch d. Br J Cancer. 2017 May 23;116(11):1462-1469. doi: 10.1038/bjc.2017.115. Epub 2017 Apr 27. Br J Cancer. 2017. PMID: 28449008 Free PMC article.
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L, Fischer LE, Heinemann V, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, Boeck S, Haas M. Weiss L, et al. Among authors: quietzsch d. ESMO Open. 2024 Apr;9(4):102944. doi: 10.1016/j.esmoop.2024.102944. Epub 2024 Mar 18. ESMO Open. 2024. PMID: 38503144 Free PMC article.
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Weiss L, Heinemann V, Fischer LE, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Vehling-Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, von Bergwelt-Baildon M, Boeck S, Haas M. Weiss L, et al. Among authors: quietzsch d. Clin Transl Oncol. 2024 May;26(5):1268-1272. doi: 10.1007/s12094-023-03323-1. Epub 2023 Oct 4. Clin Transl Oncol. 2024. PMID: 37794220 Free PMC article.
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Holch JW, Kruger S, Haas M, Michl M, von Einem J, Kirchner T, Jung A, Modest DP. Stahler A, et al. Among authors: quietzsch d. Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510. Anticancer Drugs. 2017. PMID: 28582279 Clinical Trial.
[Pheochromocytoma and shock].
Quietzsch D. Quietzsch D. Z Gesamte Inn Med. 1982 Jan 1;37(1):32-4. Z Gesamte Inn Med. 1982. PMID: 6280403 German.
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V. Fischer von Weikersthal L, et al. Among authors: quietzsch d. Eur J Cancer. 2011 Jan;47(2):206-14. doi: 10.1016/j.ejca.2010.09.022. Eur J Cancer. 2011. PMID: 20971632 Clinical Trial.
35 results